pazopanib has been researched along with Neoplasms--Neuroepithelial* in 1 studies
1 other study(ies) available for pazopanib and Neoplasms--Neuroepithelial
Article | Year |
---|---|
Leptomeningeal Dissemination of Low-Grade Neuroepithelial Tumor with FGFR1_TACC1 Fusion with Clinical and Radiographic Response to Pazopanib and Topotecan.
Low-grade neuroepithelial tumors are a heterogeneous group of central nervous system tumors that are generally indolent in nature but in rare instances can progress to include leptomeningeal dissemination.. We present a case of a patient with a low-grade neuroepithelial tumor of indeterminate type with symptomatic leptomeningeal dissemination despite 3 chemotherapy regimens and radiotherapy. Somatic targetable mutation testing showed an FGFR1_TACC1 fusion. Therapy with pazopanib/topotecan was initiated, and disease stabilization was achieved. He received pazopanib/topotecan for a total of 2 years and is now >2 years from completion of treatment and continues to do well with no evidence of disease.. This case highlights the utility of targetable mutation testing in therapeutic decision-making and the novel use of systemic pazopanib/topotecan therapy for refractory low-grade neuroepithelial tumor within the context of this clinical situation and specific mutation profile. Topics: Fetal Proteins; Humans; Indazoles; Male; Microtubule-Associated Proteins; Neoplasms, Neuroepithelial; Nuclear Proteins; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Sulfonamides; Topotecan | 2022 |